Abcellera Historical Financial Ratios

ABCL Stock

USD 2.36 0.06 2.48%

Abcellera Biologics is presently reporting on over 102 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 0.78 or Days Sales Outstanding of 447 will help investors to properly organize and evaluate Abcellera Biologics financial condition quickly.

Quick Ratio Current Ratio

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abcellera Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.

About Abcellera Financial Ratios Analysis

Abcellera BiologicsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Abcellera Biologics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Abcellera financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Abcellera Biologics history.

Abcellera Biologics Financial Ratios Chart

At this time, Abcellera Biologics' Interest Coverage is quite stable compared to the past year. Intangibles To Total Assets is expected to rise to 0.13 this year, although the value of PTB Ratio will most likely fall to 0.78.

Price To Sales Ratio Ptb Ratio Days Sales Outstanding Book Value Per Share

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Abcellera Biologics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Abcellera Biologics sales, a figure that is much harder to manipulate than other Abcellera Biologics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Ptb Ratio

Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.

Book Value Per Share

The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.

Most ratios from Abcellera Biologics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Abcellera Biologics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abcellera Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.At this time, Abcellera Biologics' Interest Coverage is quite stable compared to the past year. Intangibles To Total Assets is expected to rise to 0.13 this year, although the value of PTB Ratio will most likely fall to 0.78.

	2022	2023	2024	2025 (projected)
Days Sales Outstanding	29.02	618.0	425.55	446.83
PTB Ratio	2.34	1.43	0.82	0.78

Days Sales Outstanding Ptb Ratio

Abcellera Biologics fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Average Inventory	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow
Price To Sales Ratio		0.99	-0.72	-0.94	0.38	-0.23	0.93	0.99	1.0	0.03	0.58	0.85	0.01	-0.89	-0.34	0.44	-0.4	-0.93	0.98	-0.89	0.84	-0.98	0.3	0.94	0.15	0.98
Ptb Ratio	0.99		-0.74	-0.96	0.4	-0.23	0.89	1.0	0.99	0.04	0.52	0.87	0.01	-0.88	-0.24	0.46	-0.42	-0.95	1.0	-0.93	0.87	-0.99	0.23	0.9	0.09	1.0
Days Sales Outstanding	-0.72	-0.74		0.66	-0.73	-0.4	-0.71	-0.74	-0.72	-0.62	-0.66	-0.57	-0.57	0.58	0.28	-0.55	0.77	0.62	-0.75	0.74	-0.91	0.74	-0.34	-0.67	-0.45	-0.75
Book Value Per Share	-0.94	-0.96	0.66		-0.25	0.36	-0.78	-0.96	-0.94	0.09	-0.36	-0.83	0.08	0.82	0.12	-0.27	0.32	1.0	-0.97	0.94	-0.84	0.96	-0.11	-0.8	0.06	-0.97
Free Cash Flow Yield	0.38	0.4	-0.73	-0.25		0.71	0.58	0.4	0.38	0.87	0.72	0.1	0.84	-0.13	-0.45	0.87	-0.96	-0.19	0.41	-0.45	0.61	-0.38	0.53	0.37	0.69	0.41
Operating Cash Flow Per Share	-0.23	-0.23	-0.4	0.36	0.71		0.01	-0.23	-0.23	0.95	0.42	-0.36	0.86	0.31	-0.33	0.44	-0.64	0.42	-0.23	0.2	0.1	0.22	0.43	-0.13	0.67	-0.23
Capex To Depreciation	0.93	0.89	-0.71	-0.78	0.58	0.01		0.89	0.93	0.26	0.8	0.63	0.24	-0.74	-0.63	0.62	-0.56	-0.76	0.88	-0.77	0.79	-0.86	0.61	0.95	0.46	0.87
Pb Ratio	0.99	1.0	-0.74	-0.96	0.4	-0.23	0.89		0.99	0.04	0.52	0.87	0.01	-0.88	-0.24	0.46	-0.42	-0.95	1.0	-0.93	0.87	-0.99	0.23	0.9	0.09	1.0
Ev To Sales	1.0	0.99	-0.72	-0.94	0.38	-0.23	0.93	0.99		0.03	0.58	0.85	0.01	-0.89	-0.33	0.44	-0.4	-0.93	0.98	-0.89	0.84	-0.98	0.3	0.94	0.15	0.98
Free Cash Flow Per Share	0.03	0.04	-0.62	0.09	0.87	0.95	0.26	0.04	0.03		0.6	-0.18	0.94	0.13	-0.41	0.61	-0.83	0.16	0.05	-0.1	0.38	-0.04	0.52	0.09	0.74	0.05
Roic	0.58	0.52	-0.66	-0.36	0.72	0.42	0.8	0.52	0.58	0.6		0.15	0.65	-0.32	-0.86	0.61	-0.72	-0.32	0.5	-0.41	0.64	-0.45	0.84	0.73	0.89	0.5
Inventory Turnover	0.85	0.87	-0.57	-0.83	0.1	-0.36	0.63	0.87	0.85	-0.18	0.15		-0.32	-0.96	0.13	0.22	-0.07	-0.85	0.85	-0.73	0.61	-0.9	-0.16	0.73	-0.28	0.85
Net Income Per Share	0.01	0.01	-0.57	0.08	0.84	0.86	0.24	0.01	0.01	0.94	0.65	-0.32		0.28	-0.46	0.59	-0.88	0.15	0.04	-0.14	0.43	0.02	0.56	0.05	0.82	0.03
Days Of Inventory On Hand	-0.89	-0.88	0.58	0.82	-0.13	0.31	-0.74	-0.88	-0.89	0.13	-0.32	-0.96	0.28		0.11	-0.19	0.07	0.83	-0.85	0.67	-0.6	0.9	-0.04	-0.85	0.11	-0.85
Payables Turnover	-0.34	-0.24	0.28	0.12	-0.45	-0.33	-0.63	-0.24	-0.33	-0.41	-0.86	0.13	-0.46	0.11		-0.35	0.41	0.09	-0.21	0.11	-0.29	0.17	-0.96	-0.56	-0.84	-0.21
Average Inventory	0.44	0.46	-0.55	-0.27	0.87	0.44	0.62	0.46	0.44	0.61	0.61	0.22	0.59	-0.19	-0.35		-0.83	-0.24	0.47	-0.51	0.53	-0.44	0.46	0.4	0.5	0.47
Capex To Revenue	-0.4	-0.42	0.77	0.32	-0.96	-0.64	-0.56	-0.42	-0.4	-0.83	-0.72	-0.07	-0.88	0.07	0.41	-0.83		0.26	-0.45	0.55	-0.72	0.39	-0.52	-0.35	-0.68	-0.45
Cash Per Share	-0.93	-0.95	0.62	1.0	-0.19	0.42	-0.76	-0.95	-0.93	0.16	-0.32	-0.85	0.15	0.83	0.09	-0.24	0.26		-0.96	0.93	-0.81	0.96	-0.07	-0.79	0.12	-0.96
Pocfratio	0.98	1.0	-0.75	-0.97	0.41	-0.23	0.88	1.0	0.98	0.05	0.5	0.85	0.04	-0.85	-0.21	0.47	-0.45	-0.96		-0.95	0.89	-0.99	0.21	0.87	0.08	1.0
Interest Coverage	-0.89	-0.93	0.74	0.94	-0.45	0.2	-0.77	-0.93	-0.89	-0.1	-0.41	-0.73	-0.14	0.67	0.11	-0.51	0.55	0.93	-0.95		-0.92	0.92	-0.16	-0.71	-0.04	-0.95
Capex To Operating Cash Flow	0.84	0.87	-0.91	-0.84	0.61	0.1	0.79	0.87	0.84	0.38	0.64	0.61	0.43	-0.6	-0.29	0.53	-0.72	-0.81	0.89	-0.92		-0.85	0.33	0.74	0.35	0.88
Pfcf Ratio	-0.98	-0.99	0.74	0.96	-0.38	0.22	-0.86	-0.99	-0.98	-0.04	-0.45	-0.9	0.02	0.9	0.17	-0.44	0.39	0.96	-0.99	0.92	-0.85		-0.17	-0.86	-0.02	-0.99
Days Payables Outstanding	0.3	0.23	-0.34	-0.11	0.53	0.43	0.61	0.23	0.3	0.52	0.84	-0.16	0.56	-0.04	-0.96	0.46	-0.52	-0.07	0.21	-0.16	0.33	-0.17		0.49	0.84	0.2
Income Quality	0.94	0.9	-0.67	-0.8	0.37	-0.13	0.95	0.9	0.94	0.09	0.73	0.73	0.05	-0.85	-0.56	0.4	-0.35	-0.79	0.87	-0.71	0.74	-0.86	0.49		0.36	0.87
Roe	0.15	0.09	-0.45	0.06	0.69	0.67	0.46	0.09	0.15	0.74	0.89	-0.28	0.82	0.11	-0.84	0.5	-0.68	0.12	0.08	-0.04	0.35	-0.02	0.84	0.36		0.07
Ev To Operating Cash Flow	0.98	1.0	-0.75	-0.97	0.41	-0.23	0.87	1.0	0.98	0.05	0.5	0.85	0.03	-0.85	-0.21	0.47	-0.45	-0.96	1.0	-0.95	0.88	-0.99	0.2	0.87	0.07

Click cells to compare fundamentals

Abcellera Biologics Account Relationship Matchups

Abcellera Biologics fundamentals Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Price To Sales Ratio	46.51	10.51	5.95	43.42	29.91	28.41
Ptb Ratio	13.06	3.84	2.34	1.43	0.82	0.78
Days Sales Outstanding	333.82	156.21	29.02	618.0	425.55	446.83
Book Value Per Share	3.08	3.72	4.33	3.98	3.59	2.15
Free Cash Flow Yield	7.39E-4	0.0472	0.0709	(0.0735)	(0.22)	(0.21)
Operating Cash Flow Per Share	0.0842	0.89	0.97	(0.15)	(0.37)	(0.35)
Stock Based Compensation To Revenue	0.036	0.0817	0.1	1.69	2.34	2.46
Capex To Depreciation	2.78	3.39	2.2	2.51	0.86	0.82
Pb Ratio	13.06	3.84	2.34	1.43	0.82	0.78
Ev To Sales	43.99	9.34	5.32	41.95	26.59	25.26
Free Cash Flow Per Share	0.0297	0.67	0.72	(0.42)	(0.64)	(0.6)
Net Income Per Share	(0.0157)	0.44	0.56	(0.51)	(0.55)	(0.53)
Days Of Inventory On Hand	5.88	18.93	13.41	8.42	7.58	7.46
Payables Turnover	6.15	3.71	3.05	4.48	5.15	4.66
Research And Ddevelopement To Revenue	0.13	0.17	0.22	4.62	5.8	6.09
Capex To Revenue	0.0629	0.16	0.15	2.04	2.72	2.85
Cash Per Share	2.2	2.62	3.11	2.63	2.13	1.46
Pocfratio	477.95	16.12	10.41	(37.63)	(7.94)	(7.55)
Interest Coverage	(19.68)	23.96	39.12	53.53	48.17	50.58
Capex To Operating Cash Flow	0.65	0.24	0.26	(1.77)	(0.72)	(0.69)
Pfcf Ratio	1.4K	21.19	14.11	(13.6)	(4.61)	(4.84)
Days Payables Outstanding	59.34	98.43	119.68	81.47	73.32	72.7
Income Quality	0.19	1.59	1.75	0.3	0.67	0.63
Roe	(0.24)	0.14	0.15	0.13	(0.13)	(0.15)
Ev To Operating Cash Flow	452.03	14.33	9.31	(36.36)	(7.06)	(6.71)
Pe Ratio	91.19	25.7	18.22	(11.28)	(5.3)	(5.03)
Ev To Free Cash Flow	1.3K	18.82	12.62	(13.14)	(4.1)	(4.31)
Earnings Yield	0.011	0.0389	0.0549	(0.0887)	(0.19)	(0.18)
Net Debt To E B I T D A	(3.47)	(1.82)	(1.12)	0.29	0.47	0.49
Current Ratio	7.86	7.7	8.67	7.33	9.81	5.18
Tangible Book Value Per Share	2.54	3.01	3.7	3.4	3.28	1.83
Receivables Turnover	1.09	2.34	12.58	0.59	0.86	0.81
Shareholders Equity Per Share	3.08	3.72	4.33	3.98	3.59	2.15
Debt To Equity	0.007349	0.0355	0.0667	0.0672	0.0575	0.0546
Capex Per Share	0.0259	0.0544	0.21	0.25	0.27	0.28

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Abcellera Biologics is a strong investment it is important to analyze Abcellera Biologics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Abcellera Biologics' future performance. For an informed investment choice regarding Abcellera Stock, refer to the following important reports:

How To Invest In Abcellera

Details

Is Abcellera Stock a good investment?

Details

What is Abcellera Biologics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.

You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abcellera Biologics. If investors know Abcellera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abcellera Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.459

Earnings Share

(0.55)

Revenue Per Share

0.098

Quarterly Revenue Growth

(0.45)

Return On Assets

(0.12)

The market value of Abcellera Biologics is measured differently than its book value, which is the value of Abcellera that is recorded on the company's balance sheet. Investors also form their own opinion of Abcellera Biologics' value that differs from its market value or its book value, called intrinsic value, which is Abcellera Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abcellera Biologics' market value can be influenced by many factors that don't directly affect Abcellera Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Abcellera Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abcellera Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abcellera Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Shareholders Equity Per Share	Debt To Equity
Capex Per Share	Graham Net Net
Average Receivables	Revenue Per Share
Interest Debt Per Share	Debt To Assets
Enterprise Value Over E B I T D A	Graham Number
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

Abcellera Historical Financial Ratios

About Abcellera Financial Ratios Analysis

Abcellera Biologics Financial Ratios Chart

Price To Sales Ratio

Ptb Ratio

Book Value Per Share

Abcellera Biologics fundamentals Correlations

Abcellera Biologics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Abcellera Biologics fundamentals Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ev To Sales	+ 1.0	Price To Sales Ratio
Pb Ratio	+ 1.0	Ptb Ratio
Pocfratio	+ 1.0	Ptb Ratio
Ev To Operating Cash Flow	+ 1.0	Ptb Ratio
Cash Per Share	+ 1.0	Book Value Per Share
Pocfratio	+ 1.0	Pb Ratio

Ev To Operating Cash Flow	- 0.99	Pfcf Ratio
Pfcf Ratio	- 0.99	Pocfratio
Pfcf Ratio	- 0.99	Pb Ratio
Pfcf Ratio	- 0.99	Ptb Ratio
Pfcf Ratio	- 0.98	Ev To Sales
Pfcf Ratio	- 0.98	Price To Sales Ratio